Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel DeVido
Fast-Tracking Development Of MSC-Based Cell And Extracellular Vesicle Therapies Through A Strategic Partnership
By Daniel DeVido, PhD, Director of Strategic Business Development, FUJIFILM Biotechnologies The therapeutic potential of mesenchymal stem cells (MSCs), particularly for the regenerative medicine space, has generated significant attention in clinical research.
06.19.25 -- Multispecific Trial Supply Stability Hinges On CDMO Agility
Did you know Catalent offers contracted analytical services? With over 30+ years of experience, Catalent offers a comprehensive suite of orthogonal GMP analytical services for all biological modalities, from discovery to commercial phases. Our seasoned experts ensure exceptional on-time delivery and client satisfaction by providing tailored solutions to meet your unique needs—no matter the complexity, scale, or timeline.
07.23.24 -- More Case Studies: Managing Change In Vaccine Production
Webinar: Transforming Safety in CDMO Operations: A Customer Centric Model for Patients and Employees Save the date for August 5th for Transforming Safety in CDMO Operations: A Customer Centric Model for Patients and Employees. This webinar will highlight the unique infrastructure FDB has built around safety operations and quality, with a focus on their new product introduction process with respect to risk assessment. Click here to learn more.
Extracellular Vesicles: Building The Next Therapeutic Modality With End-To-End Product And Service Support
By Nisa Renault, FUJIFILM Cellular Dynamics Inc., and Daniel DeVido, FUJIFILM Biotechnologies Extracellular vesicles (EVs) are attracting attention for their potential as therapeutic tools and drug delivery systems. These natural messengers are unlikely to trigger immune responses, can cross the blood-brain barrier, and can be engineered to target specific cells or tissues. This versatility makes them suitable for a wide range of therapeutic applications.
01.03.24 -- FDA Warning Letters Dipped, But Don't Get Cozy
In a period marked by resource constraints, focusing R&D on the most likely molecules to succeed is paramount. But, how do you do it? Don’t miss our first Bioprocess Online Live of 2024 as we explore the most efficient approaches to scalable discovery, molecular screening and assays, definition of CQAs, establishing a proof of concept, and assessing developability. Registration is free for this January 23rd event.
09.12.23 -- A QR Code For Finding The Right CDMO
A consistent challenge for cell and gene therapy developers is finding a CDMO with the right capabilities, capacity, and timeline to meet their project needs. If this scenario sounds familiar, don’t miss the final Outsourced Pharma Capacity Update of 2023. This multiday event is conveniently grouped by molecule type and will feature cell and gene CDMO capacity presentations on October 5th. Registration is free. Is it getting more difficult to select the best CDMO?
08.01.23 -- How To Standardize Traceability Of CGTs
By BioPhorum For personalized therapies, it is imperative that patients are treated with the product meant specifically for them. Mistakes in products or on labels that lead to the wrong therapy being administered to the patient are likely to have fatal consequences. BioPhorum presents a practical vision for standardizing the traceability of cell and gene therapies across the value chain.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack